Sponsor Pipeline

Shanghai Ark Biopharmaceutical Co., Ltd. Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
5
Active Trials
3
Recruiting
3
Phase 3
1
Disease Areas
What Changed in the Last 30 Days
First PostedNew Trial FilingPhaseStatus
2026-07-22 NCT07719023 A Phase 3 Study of Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary… Phase 3 Not Yet Recruiting
Active Trials by Phase
Phase 3
2
Phase 2/3
1
Phase 1
2
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT06775405 A Study to Confirm the Effectiveness and Safety of AK0529 in Treating RSV Infections in… Respiratory Synctial Virus Infections Recruiting
NCT07719023 A Phase 3 Study of Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary… Idiopathic Pulmonary Fibrosis (IPF) Not Yet Recruiting
Phase 2/3
NCT07658534 A Study of Ziresovir (AK0529) in High-risk Adult With Respiratory Syncytial Virus (RSV)… Respiratory Syncytial Virus Infections Recruiting
Phase 1
NCT06996704 A Clinical Study of AK0610 Healthy Volunteer Study Recruiting
NCT07432698 A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AK0406 Injection in… Healthy Participants Not Yet Recruiting
Disease Areas
Get alerts when Shanghai Ark Biopharmaceutical Co., Ltd.'s trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free